<SEC-DOCUMENT>0000950123-14-002796.txt : 20140218
<SEC-HEADER>0000950123-14-002796.hdr.sgml : 20140217
<ACCEPTANCE-DATETIME>20140218164657
ACCESSION NUMBER:		0000950123-14-002796
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140218
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140218
DATE AS OF CHANGE:		20140218

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYNAVAX TECHNOLOGIES CORP
		CENTRAL INDEX KEY:			0001029142
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				330728374
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34207
		FILM NUMBER:		14622714

	BUSINESS ADDRESS:	
		STREET 1:		2929 SEVENTH STREET
		STREET 2:		SUITE 100
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
		BUSINESS PHONE:		5108485100

	MAIL ADDRESS:	
		STREET 1:		2929 SEVENTH STREET
		STREET 2:		SUITE 100
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dvax-8k_20140218.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html>
<body>
<p style="border-top:Solid 0.75pt;border-bottom:Solid 0.75pt;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:1pt;;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:7.5pt;"><font style="font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:6pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:18pt;;"><font style="font-weight:bold;color:#000000;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:18pt;;"><font style="font-weight:bold;color:#000000;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:11pt;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:7.5pt;"><font style="font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:18pt;"><font style="font-weight:bold;color:#000000;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form 8-K </font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:7.5pt;"><font style="font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:11pt;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Current Report</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:11pt;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:11pt;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:11pt;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported):&#160;&#160;February 18, 2014</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:7.5pt;"><font style="font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:24pt;;"><font style="font-weight:bold;color:#000000;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dynavax Technologies Corporation </font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:11pt;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:7.5pt;"><font style="font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:11pt;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number:&#160;&#160;001-34207</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:7.5pt;"><font style="font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p><div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:45%;"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delaware</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="bottom" style="width:10%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; </font></p></td>
<td valign="bottom" style="width:45%;"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">33-0728374</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
</tr>
<tr>
<td valign="top" style="width:45%;"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:-12.25pt;;font-size:10pt;;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="bottom" style="width:10%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; </font></p></td>
<td valign="bottom" style="width:45%;"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
</tr>
<tr>
<td valign="top" style="width:45%;"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:-12.25pt;;font-size:10pt;;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation)</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="bottom" style="width:10%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; </font></p></td>
<td valign="bottom" style="width:45%;"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
</tr>
</table></div><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:7.5pt;"><font style="font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-weight:bold;;font-size:11pt;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2929 Seventh Street, Suite 100</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:11pt;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Berkeley, CA 94710-2753</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices, including zip code)</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:7.5pt;"><font style="font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:11pt;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(510) 848-5100 </font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code)</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:7.5pt;"><font style="font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former name or former address, if changed since last report) </font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:7.5pt;"><font style="font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p><p style="margin-bottom:12pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-weight:bold;;font-size:10pt;;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[&#160;&#160;]&#160;&#160; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br><br>[&#160;&#160;]&#160;&#160; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br><br>[&#160;&#160;]&#160;&#160; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br><br>[&#160;&#160;]&#160;&#160; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:11pt;">&nbsp;</p><p style="border-top:Solid 0.75pt;border-bottom:Solid 0.75pt;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:1pt;;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-weight:bold;;font-size:10pt;;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 8.01. Other Events</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:11pt;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:4.54%;font-size:10pt;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%">On February</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 18, 2014, we issued a press release titled "Dynavax Announces Withdrawal of European Marketing Application for HEPLISAV&#8482;." A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference. </font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-weight:bold;;font-size:10pt;;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01. Financial Statements and Exhibits</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:4.54%;font-size:10pt;;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:4.54%;font-size:10pt;;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%">(d) Exhibits. </font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:4.54%;font-size:10pt;;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%">The following exhibit is furnished herewith: </font></p><p style="margin-bottom:0pt;margin-top:12pt;margin-left:0%;margin-right:0%;text-indent:4.54%;font-size:10pt;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%">EX-99.1 Press Release, dated February</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 18, 2014, titled "Dynavax Announces Withdrawal of European Marketing Application for HEPLISAV&#8482;". </font></p><p style="margin-bottom:0pt;margin-top:6pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;">&nbsp;</p><p style="margin-bottom:10pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-weight:bold;;font-size:10pt;;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br></font></p>

<div style="width:100%;"><hr style="page-break-after:always"></div><p style="margin-bottom:10pt;margin-top:0pt;margin-left:0%;margin-right:0%;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Signature(s)</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:4.54%;font-size:10pt;;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;">&nbsp;</p><div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:27.25pt;">
<td valign="top" style="width:30%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;">&nbsp;</p></td>
<td valign="top" style="width:10%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;">&nbsp;</p></td>
<td valign="top" style="width:60%;"><p style="margin-bottom:18pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-weight:bold;;font-size:10pt;;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">Dynavax Technologies Corporation</font></p></td>
</tr>
<tr style="height:13.85pt;">
<td valign="top" style="width:30%; border-bottom:solid 0.75pt transparent;"><p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date February 18, 2014 </font></p></td>
<td valign="top" style="width:10%; border-bottom:solid 0.75pt transparent;"><p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;">&nbsp;</p></td>
<td valign="top" style="width:60%; border-bottom:solid 0.75pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: /s/ Michael S. Ostrach</font></p></td>
</tr>
<tr style="height:21.65pt;">
<td valign="top" style="width:30%; border-top:solid 0.75pt transparent;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;">&nbsp;</p></td>
<td valign="top" style="width:10%; border-top:solid 0.75pt transparent;"><p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;">&nbsp;</p></td>
<td valign="top" style="width:60%; border-top:solid 0.75pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:21.6pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael S. Ostrach</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:21.6pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President</font></p></td>
</tr>
</table></div><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:4.54%;font-size:10pt;;">&nbsp;</p><p style="margin-bottom:10pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:11pt;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></font></p>

<div style="width:100%;"><hr style="page-break-after:always"></div><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:10pt;;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT INDEX</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:11pt;">&nbsp;</p><div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;"><font style="font-weight:bold;text-decoration:underline;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;No.</font><font style="text-decoration:underline;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="top" style="width:5%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom" style="width:90%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;"><font style="font-weight:bold;text-decoration:underline;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</font><font style="text-decoration:underline;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
</tr>
<tr>
<td valign="top" style="width:5%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EX-99.1 </font></p></td>
<td valign="top" style="width:5%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;">&nbsp;</p></td>
<td valign="top" style="width:90%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-size:10pt;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Press Release, dated February 18, 2014, titled &#8220;Dynavax Announces Withdrawal of European Marketing Application for HEPLISAV&#8482;".&nbsp;&nbsp;</font></p></td>
</tr>
</table></div><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>dvax-ex99_2014021814.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
<body>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-family:Arial;font-weight:bold;;font-size:11pt;;"><font style="font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:57.14%;margin-right:0%;text-indent:0%;font-family:Arial;font-size:10pt;;"><img src="g20140218180336539724.jpg" alt="logo" style="width:160.5pt;height:47.25pt"><font style="color:#0000FF;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:65.31%;margin-right:0%;text-indent:-8.16%;font-family:Calibri;font-weight:bold;;font-size:10pt;;"><font style="font-weight:bold;color:#145590;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;2929 Seventh Street, Suite 100&nbsp;&nbsp; </font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:65.31%;margin-right:0%;text-indent:-8.16%;font-family:Calibri;font-weight:bold;;font-size:10pt;;"><font style="font-weight:bold;color:#145590;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Berkeley, CA 94710</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-bottom:6pt;margin-left:65.31%;margin-right:0%;text-indent:-8.16%;font-family:Arial;font-weight:bold;;">&nbsp;</p><div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="padding-left:5.4 pt;padding-Right:5.4 pt;padding-Top:0 pt;padding-Bottom:0 pt;width:45%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.13%;text-indent:0pt;;font-family:Arial;font-weight:bold;;font-size:11pt;;"><font style="font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Contact:</font></p></td>
<td valign="top" style="padding-left:5.4 pt;padding-Right:5.4 pt;padding-Top:0 pt;padding-Bottom:0 pt;width:10%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:4.99%;text-indent:0pt;;font-family:Arial;font-size:11pt;;">&nbsp;</p></td>
<td valign="top" style="width:45%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-family:Arial;font-size:11pt;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4 pt;padding-Right:5.4 pt;padding-Top:0 pt;padding-Bottom:0 pt;width:45%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-family:Arial;font-size:11pt;;"><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael S. Ostrach</font></p></td>
<td valign="top" style="padding-left:5.4 pt;padding-Right:5.4 pt;padding-Top:0 pt;padding-Bottom:0 pt;width:10%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:4.99%;text-indent:0pt;;font-family:Arial;font-size:11pt;;">&nbsp;</p></td>
<td valign="top" style="width:45%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-family:Arial;font-size:11pt;;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="padding-left:5.4 pt;padding-Right:5.4 pt;padding-Top:0 pt;padding-Bottom:0 pt;width:45%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-family:Arial;font-size:11pt;;"><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President, Chief Business and</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-family:Arial;font-size:11pt;;"><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Principal Financial Officer </font></p></td>
<td valign="top" style="padding-left:5.4 pt;padding-Right:5.4 pt;padding-Top:0 pt;padding-Bottom:0 pt;width:10%;"><p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-family:Arial;font-size:11pt;;">&nbsp;</p></td>
<td valign="top" style="width:45%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-family:Arial;font-size:11pt;;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="padding-left:5.4 pt;padding-Right:5.4 pt;padding-Top:0 pt;padding-Bottom:0 pt;width:45%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-family:Arial;font-size:11pt;;"><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">510-665-7257</font></p></td>
<td valign="top" style="padding-left:5.4 pt;padding-Right:5.4 pt;padding-Top:0 pt;padding-Bottom:0 pt;width:10%;"><p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-family:Arial;font-size:11pt;;">&nbsp;</p></td>
<td valign="top" style="width:45%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-family:Arial;font-size:11pt;;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="padding-left:5.4 pt;padding-Right:5.4 pt;padding-Top:0 pt;padding-Bottom:0 pt;width:45%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-family:Arial;font-size:11pt;;"><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mostrach@dynavax.com</font></p></td>
<td valign="top" style="padding-left:5.4 pt;padding-Right:5.4 pt;padding-Top:0 pt;padding-Bottom:0 pt;width:10%;"><p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-family:Arial;font-size:11pt;;">&nbsp;</p></td>
<td valign="top" style="width:45%;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0%;text-indent:0pt;;font-family:Arial;font-size:11pt;;">&nbsp;</p></td>
</tr>
</table></div><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-family:Arial;font-weight:bold;;font-size:11pt;;">&nbsp;</p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-family:Arial;font-weight:bold;;font-size:11pt;;">&nbsp;</p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-family:Arial Bold;font-weight:bold;;font-size:11pt;;"><a name="OLE_LINK9"></a><font style="font-weight:bold;font-size:11pt;font-family:Arial Bold;text-transform:uppercase;font-style:normal;font-variant: normal;">DYNAVAX ANNOUNCES WITHDRAWAL OF EUROPEAN MARKETING APPLICATION FOR HEPLISAV&#8482;</font></p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-family:Arial;font-weight:bold;;font-size:11pt;;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-family:Arial;font-size:11pt;;"><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BERKELEY, CA &#8211; February 18, 2014 &#8211; Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it has withdrawn the European Marketing Authorization Application (MAA) for HEPLISAV, its investigational hepatitis B vaccine.&nbsp;&nbsp;The Day 180 List of Outstanding Issues provided by the European Medicines Agency (EMA) indicated that the current HEPLISAV safety database is considered to be too small to rule out a risk of less common serious adverse events.&nbsp;&nbsp;Dynavax has chosen to withdraw the application because the required timeframe for response under the MAA procedure is not long enough to permit the collection of the necessary clinical data.&nbsp;&nbsp;Dynavax expects to begin shortly an additional HEPLISAV clinical trial, HBV-23, that is intended to provide a safety database sufficient to support licensure.</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-family:Arial;font-size:11pt;;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-family:Arial;font-weight:bold;;font-size:11pt;;"><font style="font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">About HEPLISAV</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-family:Arial;font-size:11pt;;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-family:Arial;font-size:11pt;;"><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HEPLISAV is an investigational adult hepatitis B vaccine that combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist to enhance the immune response. Dynavax has worldwide commercial rights to HEPLISAV.</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-family:Arial;font-size:11pt;;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-family:Arial;font-weight:bold;;font-size:11pt;;"><font style="font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">About Dynavax</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-family:Arial;font-size:11pt;;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-family:Arial;font-size:11pt;;"><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com.</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-family:Arial;font-size:11pt;;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-family:Arial;font-weight:bold;;font-size:11pt;;"><font style="font-weight:bold;color:#000000;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-family:Arial;font-size:11pt;;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-family:Arial;font-size:11pt;;"><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release contains "forward-looking" statements, including expectations for the timing and sufficiency of an additional clinical trial for HEPLISAV. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including whether successful clinical and regulatory development and review and approval of HEPLISAV and our process for its manufacture can occur without significant delay or additional studies; whether our studies and manufacturing efforts are sufficient to support registration for commercialization of HEPLISAV in either or both of the US and&#160;Europe; the timing for and costs of achieving the size of the safety database; the results of clinical trials and the impact of those results on the initiation and completion of subsequent trials and issues arising in the regulatory process, including </font></p><p style="margin-bottom:0pt;margin-top:12pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:11pt;">&nbsp;</p>

<div style="width:100%;"><hr style="page-break-after:always"></div><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:11pt;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;"><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">whether a US or European licensure application will be approved; our ability to obtain additional financing to support the development and commercialization of HEPLISAV and our other operations; possible claims against us, including enjoining sales of HEPLISAV, based on the patent rights of others; and other risks detailed in the "Risk Factors" section of our current periodic reports with the&#160;SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Information on&#160;Dynavax's&#160;website at&#160;</font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">www.dynavax.com</font><font style="color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;is not incorporated by reference in our current periodic reports with the&#160;SEC.</font></p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-family:Arial;font-size:11pt;;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-family:Arial;font-size:11pt;;">&nbsp;</p><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:11pt;font-family:Arial;"><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"># # #</font></p><p style="margin-bottom:0pt;margin-top:12pt;line-height:10pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:11pt;">&nbsp;</p><p style="margin-bottom:0pt;margin-top:0pt;line-height:10pt;margin-left:0%;margin-right:0%;text-indent:0%;font-size:11pt;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g20140218180336539724.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g20140218180336539724.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`$9`Z<#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`**9+-%"`994C!Z%V`S6?+XAT:#[^IVO7&%E#'
M]*`-.BL%_&?A]&*G41D>D3D?F%JM_P`)]H?_`#TG_P"_1H"YT]%<G)\0]&1L
M+%>2#^\L:X_5A3/^%C:1_P`^U]_WPG_Q5`7.OHKD/^%C:1_S[7W_`'PG_P`5
M4D7Q"T:0D,EW'CNT8Y_(F@+G5T5S<?CO07;#7$D8QU:)L?IFKL'BC0[C&S4X
M!G_GH=G_`*%B@#7HIJ2)*@>-U=3T93D&G4`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`'G_B'QOJ-EJES8VD4$:Q-M\Q@68_T_2N6N?$>LW>?-U*XP<Y
M"/L!S[+@5U6J^!]1U37+N[$UO%!+(2NYB6QCT`_K3(?AK*2?.U-%';9$6S^9
M&*9.IPKNTC%G8LQZDG)-)79Z]X%&F:9+>VUXTHB`+QNH!(SU!_I7&4P"BBB@
M04^*&68D11/(1U"J3BO0/`&EV%SI4UU<6D,LZW!17D4-@!5(QGIR>M=RB+&@
M5%"J.@`P!2N.QX7]AO/^?6?_`+]FHY8)H,>;$\>>F]2,U[S2,H=2K`%2,$$<
M$47'8\#HKV:^\,:-J`/G6,2N>=\0V-^G7\:X_5_A[<0`RZ7-]H0?\LI"`_X'
MH?THN*QQ]M>7-G)YEM<2POZQN5/Z5T^F?$#4K3"7J)>1CN?D?\QQ^8_&N4DB
MDAE:.5&213AE88(/H13:8'LVC^)--UL;;:7;/C)ADX8?X_A6O7@:.T;JZ,59
M3D,#@@^M=[X9\<G*6>L2<=$N3_)O\?S]:5AIG?T4`@@$'(/0BBD,****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`R/%/_(KZA_UR/\Z\9KV;Q3_R*^H?]<C_`#KQ
MFFB6%%%%,1Z=\.?^1>N/^OIO_0$KKZY#X<_\B]<?]?3?^@)77U):"BBB@`HH
MHH`P_$7AFUUVW+86*\4?NYL?HWJ/Y5Y+>6=QI]W):W49CFC.&4_S^E>[5ROC
M7P^NI:<U[`G^EVRD\=73N/?'4?CZTT)H\LHHHIDG:^#?%C6LD>F7\G^C-Q%*
MQ_U9]"?3^7TZ>D5X%7J/@CQ`VIV365R^ZZMQP3U=.F3[@\?E2929UE%%%(84
M5YGK_B[6K37;RWMKORH8I"BKY2'@?4&L]/&_B!6!-\&`_A,*8/Y"G85SURBO
M*D\?ZXA4LUNX'4-%U_(BK*?$;5`X,EK9LO<*K`_GN-%@N>F45YS_`,+)O/\`
MH'P?]]FD;XD7I4[;"W#8X)9B,T6"YZ/17GVC>-]3U+7+.UFCMDBD?:PC0@G(
M]237H-(84444`%%<9XT\0:EHU_:+93A$>,LRE%8,<^XS7.?\)]KG_/2#_OT*
M=A7/5J*\S3XC:H'!DM;-E[A58'\]QHD^(^J%OW=I9JOHP8G\]PHL%STRBN2\
M)>)K[7KRYCND@18HPP$2D<Y]R:ZVD,**\OO/'&N6][/#NA7RY&3!BY&#BH3X
M]UT@CS81[^4*=A7/5J*\H3QYKJJ`9H6(_B,0R?RI)/'>O.N%N(HS_>6)<_KF
MBP7/6**\IL_'>M07<<ES.+B$'YXC&BY'U`R#7I6FZG::M:+<V<H=#P1W4^A'
M8T@N7****!A1110`4444`%%>5O\`$#6W<LIMD!_A6/@?F33'\>:ZRD":%2?X
MA$,C\Z=A7/5Z*\A_X37Q#_T$/_(,?_Q-12>+=>E?<VI2@_[(51^0%%@N>QT5
MY#9>)=<FO[>,ZA.X:105]1FO7J07"BBB@84444`%%%%`!17B_B34O[5UZZN5
M;,>[9'Z;1P,?7K^-+X:U0Z3KMO<%ML3'RY?38>N?IP?PIV%<]GHHHI#"BBB@
M`HK@?B!J%[97UFMK>7$"M$21%*R@G/L:Y:+Q1KD(4+J=P=IR-[;OSSG-.PKG
ML]%>0_\`":^(?^@A_P"08_\`XFK`\>ZZ`!YL)]_*%%@N>K45Y0_CS764@30J
M3_$(AD?G59_&7B"1"K:BP!_NQHI_,"BP7/8**\4D\0ZS(VYM4O`?]F9E'Y`U
MZ%X"N[F\T*>2ZN)9W%RRAI7+$#:O&3]:+!<ZFBBN*^($M]!_9TUF]Q'L\W>\
M)8;?N]2/Q_6D,[6BO%HO$FM1`A=4NCG^](6_G5I?&GB!5"C4#@#',2$_GMIV
M%<]?HKR'_A-?$/\`T$/_`"#'_P#$U#-XLUV?._4I1D8^0!/_`$$#\Z+!<]DH
MKS#P?<:M?^([66:>]N+:+?O=W9T7*'&2>!SBO3Z0PHHHH`***\[^(VI"2YMM
M-0\1#S9.>,G@#Z@9_P"^J`/1**\$C=HI%D1BKJ0RL.H(KVS1=175='MKT?>D
M3YQZ,.&'Y@T"3+]%%%`PHHHH`****`"BF3>9Y,GE8\S:=N>F>U>2?\)KXA_Z
M"'_D&/\`^)H%<]>HKR(>-O$((/V_/MY,?_Q-7(_B'K*+AHK.0_WFC;/Z,*=@
MN>HT5YPOQ(O0HW6%N6QR0S`9J.7XCZD2/*L[11WW!F_J*+!<]+HKRN7X@:W(
M<K]FBXQA(_UY)K8\&>(-6U?6I(+V\\R)(&DV^6@R<J.H`/>BP7.\HHK@O%'B
M[4=+UV6SLY(O+C5<AH\D$C/7\12&=[17E/\`PGVN?\](/^_0H_X3[7/^>D'_
M`'Z%.PKGJU%>8#XBZP`!]GLC[E&_^*J.7X@ZU(056UCQV6,\_F318+GJ=%>?
M^$/$NK:GKJVUY=>;"8V.WRU7D>X`KT"D,****`"BBB@`HHHH`****`"BBB@#
M(\4_\BOJ'_7(_P`Z\9KV;Q3_`,BOJ'_7(_SKQFFB6%%%%,1Z=\.?^1>N/^OI
MO_0$KKZXOX;R$Z3=Q8&U9]P]<E1_@*[2I+04444`%%%%`!1110!XYXJTI=(U
MZ:",8AD_>Q#T4]OP((_"L6O1OB/9;[&TOE',<AC8CT89'ZC]:\YIDL*N:5J$
MFE:G!>Q=8FR1_>'<?B*IT4Q'O4,R7$$<T;;HY%#J?4$9%/KE_`5_]K\.B!C\
M]LYC_P"`GD?S(_"NHJ2R&XL[6[7;<VT,P])$#?SKA/%W@Z&WMFU'2XMB1C,T
M(R0!_>'T[BO0:"`001D'J#0!X%170^+]"_L75=T*XM+C+Q8Z*>Z_A_(USU40
M%>CZ9X$T>YM(;HW5S<)*H=<$("".XP3G\:\XKNO`&N^5*VD7#`(Y+P,3T;NO
MX]?S]:3&CK;#PSH^FR)+;62"5>DCDL0?7D\?A6M112*"BBB@"K>:;9:@`+RT
MAGP,`R("1]#VKF/$/A?0++1;N\6W,$B(61DD;ES]T8)(QDBNQKS/Q[K9N[\:
M9"W[FV.9,'AG_P#K?U-`F<>B-(ZHBEF8X"@9)/I7H&B_#Z(P1SZM(YD89,$9
MP%]B>_X8IG@'0/\`F,W*>JVZG\BW]!^/M7?TVP2*.GZ-I^E;OL-JD)8`,1DD
MCZGFKU%%(9FW>@:3?%FN-/MV=R2SA-K$GN2.:Y[5?A[931.^FR/;R@?+&[;D
M/MSR/KDUV=%`'A-Y9W&GW<EK=1F.:,X93_/Z5!7H'Q)M$V6-X%P^6B8XZCJ.
M?;G\Z\_JB0K2T76KK0[X7%N<J>)(R?E<>A_H:S:*!'M^E:K:ZS8K=6KY4\,I
M^\A]#5ZO%-%UJZT.^%Q;G*GB2,GY7'H?Z&O7=*U6UUFQ6ZM7RIX93]Y#Z&I*
M3+U%%%`PHHHH`R;OPSHMZQ:?3H=QZE`4)_[YQ7,Z]X#LX-/GO-/EE1X4,AB<
M[@P`R0#U!_.N\JO?_P#(/N?^N3?R-`K'A5>@^&_`UM):0WVIGS?-0.D"D@`$
M9&3US[?SKSZO;M$8MH&G,Q)8VL1))Y)VBFQ(EL]-LK`8M+2&#(P2B`$_4]ZM
M444B@HHHH`****`"L7Q7J1TOP]<RH<2R#RH^<<MQD>X&3^%;5>;?$34?.U*#
M3T(VVZ;WP?XF['Z`#\Z!,XNBBBJ)/7_!^J#4_#T&YLS0#R9,]>.A_$8Y]<UO
M5Y;X"U3[%K9M'/[J[&WKT<<C^H_$5ZE4E(****!D-Q:6UVFRYMXIE_NR(&'Z
MUC:AX.T6^B8+:+;R'.V2'Y<'Z=/TK?HH`\-U+3YM*U":RN`/,C.,CH1V(JI7
MH?Q$T@R0PZM$.8\13?[I/RG\SC\17GE,EA75^#/#5KK;3W%ZS-#"P41*<;B?
M4^GTKE*ZOP#J7V/73:N<1W:;?^!#D?U'XT`CT2#1M,MAB'3[5.,9$2Y/U/>K
MU%%(H****`*UQI]E=AOM%I!+NZ[XP<_G7F?C70K/1KRW:R^1)U8F(MG:01R.
M^#G]#7JM>2^-]0^W>))45LQVP$*\\9'+?J2/PIH3,"""6YN(X(4+RR,%11W)
MKT_2/`NFV*))>+]KN!@G?]P'V7N/K7/_``]TK[1J,NI2#]W;C8GNY']!_,5Z
M50P2&QQI%&J1HJ(HP%48`%.HHI#"BBB@!LDB11M([!44%F8]`!7B&JW[ZGJE
MS>OG,KE@#V'0#\!@5Z9XXU+[!X>>)&Q+='RACKM_B_3C\:\GIHEA7=_#K5-D
MMQIDC</^]BR>XX8?E@_@:X2K>F7TFF:G;WL>=T+AB!W'<?B,C\:8'N5%,AF2
MX@CFC;='(H=3Z@C(I]24%%%%`!1110`5DS^&-$N,[],MQD8_=KL_]!Q6M10!
MY_K_`(!2&WDNM)=R4&YK=SG([[3_`$/Y]JX*O?:\O\;^'O[.O/[0MU_T6X;Y
M@!_JW]/H>3^?M30FCDJ***9)Z3X:\,>'[_1[:\,+7$C*/,WR'Y7'WA@8XSZ]
ML5U5GIECI^?LEI!`2,$QH`2/<]37F?@O7_[)U+[/.^+2Y(#9Z(W9OZ'_`.M7
MJU)E(*R]0\.Z3JLXGO;,22@8W;V4X_`BM2BD,Y:^\$^'UM99?*DMEC0LSI*3
M@`9S\V:\KKT#Q]KX"?V/;L"3AK@@].X7^OY5Q6FZ=/JM_%9VRYDD.,GHH[D^
MPIHEEK0M`N]>NS%!\D:<R3,/E3_$^U=]:_#_`$:``S^?<GOO?:/_`!W'\ZV]
M(TFVT;3X[2W4<#+OCEV[DU?HN.Q2LM'T[3B&M+*"%\8WJ@W8]-W6KM%%(844
M44`%%%%`!1110`4444`%%%%`&1XI_P"17U#_`*Y'^=>,U[-XI_Y%?4/^N1_G
M7C--$L****8CT;X;?\@^^_ZZK_*NWKB_AO&PTJ\D/W6G"CZA1G^8KM*EE(**
M**!A1110`4444`8/C.W%QX5O.FZ,+("3TPPS^F:\@KVOQ`BR>'=25AD"VD;\
M0I(_45XI31+"BBBF([7X;W)35+RVSQ)"'_%3C_V8UZ17DW@641^*K=2,^8CJ
M/;Y2?Z5ZS292"BBBD,S==TB+6]*ELY,!C\T;G^%QT/\`3\:\8G@EMKB2"9"D
ML;%74]B*]YKAO'OA_P`Z/^V+9,R(`+A0.J]F_#H?;'I30FCSNE1VC=71BK*<
MA@<$'UI**9)[#X6UY==TL.YQ=0X6=??LWT./YUN5XOX>UE]#U:.Z`W1'Y)5]
M5/7\1UKV6&:.X@2:%P\;J&5AT(-2RD/HHJ.>>*VMY)YG"11J6=CV`H&97B;7
M%T/2FE!!N9,I"I&?F]?H*\QT#1Y=>U=8"6\O.^:0\X7OSZFEUW5Y_$.L&54;
M:2(X(NX&>/Q->F^&=#70]*6(@&YDP\S`Y^;T^@IBW-:&&.W@2&%`D:*%51T`
M%/HHI#"BBB@`HHHH`Y#XC?\`(O6__7TO_H#UP.C:3+K5\;2&14D\MG7=T)';
MVKOOB-_R+UO_`-?2_P#H#UR7@AV3Q;:*IP'$BM[C83_,"F2]S#N;::TN)+>X
MC:.6,X96Z@U%7L/B+PU;:];$X6*\4?NYL?HWJ/Y5Y/?Z?=:9=M:WD1BE7G![
MCU![B@&BM6EHNM76AWPN+<Y4\21D_*X]#_0UFT4Q'M^E:K:ZS8K=6KY4\,I^
M\A]#5ZO%-%UJZT.^%Q;G*GB2,GY7'H?Z&O7=*U6UUFQ6ZM7RIX93]Y#Z&I*3
M+U%%%`PHHHH`\$D1HI&C<8925(]"*]KT+_D7M-_Z]8O_`$`5X[JD9AU:]B8@
MLD[J<=,AC7L.@L&\.Z:5((^RQC@]PHILE&C1112*"BBB@`HHHH`CGFCMK>6>
M4XCB0NQ]`!DUX=?7<E_?3W<OWYG+D>F>U>E>/M2^QZ$MJIQ)=OM_X".3_0?C
M7G.E6#ZGJEM9)G,KA21V'4G\!DTT)E1E*G#`@X!Y'8TE=M\0-'6UGMM0@C5(
MG40N%'1E'R_^.C'_``&N)IB'Q2R03)-$Q22-@RL.H(Y!KV[2K]=3TNVO4QB5
M`2!V/0C\#FO#J[_X=:IQ<:7(W_3:+)^@8?R/YTF".^HHHI%!1110!!>6L=]9
M3VLH_=S(4/MD=:\0O;22PO9K2;_61.4..^.]>[5YQ\1-+,-]#J2+\DX\N0C^
M^.F?J/\`T&FA,XFI()I+:XBGB.V2)PZGT(.14=%,D]TT^]CU'3[>\B^Y,@<#
M.<>H_#I5FN'^'>J&6UGTN1LM%^]B'^R3R/S.?^!5W%26%%%%`%>^NEL;"XNG
M(VPQL_/?`Z5X9)(\TKRR-N=V+,?4GK7IGQ!U(6VCQV*-^\NF^8?["\_SQ^M<
M;X2TW^T_$5O&PS'%^^D^B_\`U\"FA,],\.:9_9.A6UJ1B7;OE_WSR?RZ?A6K
M112&%%%%`!11574;V/3M.N+R3[L*%L>I[#\3@4`>:>.]2^VZ^;=&)BM%\L#M
MN/+'^0_"N7P<9QQZT^662>9YI6+R2,69CU)/)-=]/X8_XM]$JQ@WD8^U\#DY
MY(_[YP/JHID[GGU%%%,1Z?\`#_5!=:,UB[9EM6X![H>1^N1^5==7COA35?[)
MUZ"5SB&7]U+[`]_P.#7L5)E(****0PHHHH`****`"H+RTAO[.6UN%W12KM85
M/10!XGK>DRZ+JDMG(2P7YHW(QO4]#_3Z@UG5ZSXQ\/G6M-$L"YO+?+1C^^.Z
M_P!1[_6O)B""01@CJ*9+"O2O`_B/[;;C2[I_](B7]RQ_C0=OJ/U'TKS6I;:X
MEM+F.X@<I+&P96'8B@#WBLCQ'KD>A:6TYPT[_+#&3]YO7Z#K_P#KI-)\0VFH
M:%_:4LB0B,8N`>B,.OY]OJ.]>8^(]<DUW5&G.5@3Y88R?NKZ_4]?_P!5`VS-
M=YKRZ9W+RSRODGJ68FO6/"GAU=#L-TRJ;V89E8<[1V4'^?O6)X&\->6BZO>1
M_.PS;HPZ#^_^/;\_2N[H8)!1112&%%%%`!1110`4444`%%%%`!1110`4444`
M9'BG_D5]0_ZY'^=>,U[-XI_Y%?4/^N1_G7C--$L****8CT[X<_\`(O7'_7TW
M_H"5U]<?\.74Z#<H#\PN22/8JN/Y&NPJ2T%%%%`!1110`4444`9^N_\`(O:E
M_P!>LO\`Z`:\2KV?Q/-Y'AG47W`9A*9/^UQ_6O&*:)84444Q'0>"03XNLL#I
MYF?^^&KUVO+/A]&7\2E@1B.!V.?3(']:]3I,I!1112&%(Z+(C(ZAD8892,@C
MTI:*`/&_$VAOH>JM$`3;29>%B<_+Z'W%8U>S^(=%CUS2GMC@3+\T3_W6_P`#
MTKQN:&2WG>&9"DB,593U!%-$L97H/P_UW<K:/._*Y>W)/4=2O\S^=>?5)!/+
M;7$<\+E)8V#(P[$4P/>:\U\<^(OMEP=+M7S;Q-^]8'[[CM]!_/Z5?U3QRDGA
MN(VC;-0G!1PO_+''4_CV_P#K5S7A70#KFIA9`PM(OFF8=_1?Q_QI#;.A\!^'
M>FL72^UNI_5C_3\?:N_I$18T5$4*BC"J!@`>E+2&%%%%`!1110`4444`<M\0
M$5_#.YADI.C+['D?R)KBO!7_`"-UC_VT_P#1;5V_C[_D6'_ZZI_.N(\%?\C=
M8_\`;3_T6U,3W/7JR=>T"UUZS\J;Y)5YBF`R4/\`4>U:U%(9XAJNE76CWS6M
MTF&'*L/NN/451KVO6M%M=<L3;W`PPYCE`^9#ZC^HKR+5=*NM'OFM;I,,.58?
M=<>HIDM%&M+1=:NM#OA<6YRIXDC)^5QZ'^AK-HIB/;]*U6UUFQ6ZM7RIX93]
MY#Z&KU>*:+K5UH=\+BW.5/$D9/RN/0_T->NZ5JMKK-BMU:OE3PRG[R'T-24F
M7J***!GB6N_\C#J7_7U+_P"AFO5?"C!O"^GE2"/*QP>X)KRWQ#&8O$>I*Q&3
M<.W'H23_`%KTOP5_R*-C_P!M/_1C4V2C?HHHI%!1110`4451UC4!I>D75Z1D
MQ)E1ZL>!^I%`'F?C;4O[0\12QJ?W=M^Y7ZC[WZY'X5K?#G3?,NKG4G7Y8QY4
M9/\`>/)_3'YUP[,68LQ)8G))/)->S>&]-_LK0;6V9<2[=\GKN/)S].GX4R42
M:]IO]K:)=68`,CIF//9QR/IR,?C7BA!!((P1U%>^UY%XSTW^SO$4Y12(;C]\
MGX_>_7/Z4(;.?JYI5^^EZK;7J=8GR1ZCH1^()JG13)/>XI$FB26-MR.H93Z@
M]*=7+>`]3^W:"+9VS+:-L_X">5_J/PKJ:DL****`"LOQ%I@U?0[FU'^LV[XS
MCHXY'Y]/QK4HH`\"(()!&".HHKH/&6E?V9K\I10(;C]ZF.V>H_//Z5S]407]
M%U)])U>WO$/"-\X_O*>"/RKVR.1)8UD1@R,`RL.A!KP2O4O`>J_;M%-I(?WM
MH=@]T/W?ZC\!292.KHHK/UO41I6C75X3AHT.SC/S'A?U(I#/,?&.HG4?$=QA
MLQ0?N4Q[=?US76_#W3?L^DRWSKA[E\+D?P+_`(G/Y"O.;6WDO;V&WCYDFD"#
M/J3BO<;.UCLK.&UA&(XD"+^`IL2)J***0PHHHH`*XCXBZEY5E;Z<A^:9O,D_
MW1T'XG_T&NWKQGQ/J7]J>(+J=3F)6\N/_=7C/X\G\::$QGAS3O[5UZUMB`8]
M^^3(XVKR1^.,?C7M)`(((R#U!KA?ASIVRWNM2<#,A\F/CD`<G\SC\J[JA@CQ
M7Q!IO]DZY<V@'[L-NC_W3R/\/PK,KT3XC:;YEK;:DB_-&?*D(_NGD?KG\Z\[
MH$PKV/PIJ?\`:OAZWE8YEC'DR?[R]_Q&#^->.5V'P]U/[-JTM@[?)=+E?]]>
M?U&?R%#!'IM%%%(H****`"BBB@`HHHH`*\V\=>'OLEQ_:MJF()3B90,!']?H
M?Y_6O2:CG@BN;>2"9`\4BE74]P:`/!J*U_$FB2:%JKP?,;=_GA<]U]/J.GZ]
MZR*H@>LTJ121+(RQR8WJ#PV.F:Z3P?X;.L7GVFY7_086^8$?ZQO[H]O7_P"O
M7,5V/@;Q#]BNAIET_P#H\S?NB3]QSV^A_G2&CTP````8`Z`4444B@HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`R/%/\`R*^H?]<C_.O&:]F\4_\`(KZA
M_P!<C_.O&::)84444Q'HWPV_Y!]]_P!=5_E7;UQ_PY4#0+AL#<;I@3CG&U?\
M3785+*04444#"BBB@`HHHH`Y?Q]<^1X9:+O/*B?E\W_LM>55V_Q'OA)?6EBI
M_P!4AD?ZMP/T'ZUQ%-$L****8CO_`(;6AVW]X<[25B7TSU/\UKOJR/#.FG2M
M`MK=UVRE?,E!Z[FYP?IP/PK7J2T%%%%`!1110`5Q/CSP\MQ;'5[9`)HA^_`_
MC7IGZC^7TKMJ;)&DL;1NH9&!5E/0@T`>"45)<1"&YEB!R$<J#ZX-1U1`5[/X
M<TR'2]$MX8@-SH))&_O,1R?Z5XQ7NMA_R#[;_KDO\A28T6****104444`%%%
M%`!1110!RWQ`=4\,[6."\Z*ON>3_`"!K@O"W_(SZ?_UU'\J[?XC?\B];_P#7
MTO\`Z`]<1X6_Y&?3_P#KJ/Y4T2]SV:BBBD4%9NM:+:ZY8FWN!AAS'*!\R'U'
M]16E10!XAJNE76CWS6MTF&'*L/NN/451KVO6M%M=<L3;W`PPYCE`^9#ZC^HK
MR+5=*NM'OFM;I,,.58?=<>HIDM%&M+1=:NM#OA<6YRIXDC)^5QZ'^AK-HIB/
M;]*U6UUFQ6ZM7RIX93]Y#Z&KU>*:+K5UH=\+BW.5/$D9/RN/0_T->NZ5JMKK
M-BMU:OE3PRG[R'T-24F>5>+HS%XJOU8@DN&X]"H/]:]"\$.K^$[15.2AD5O8
M[R?Y$5P7C7_D;K[_`+9_^BUKM_`/_(L)_P!=7_G3!;G3T444AA1110`5P7Q&
MU+"6NFHW4^=(!^2C^?Y"N])`!).`.I->*:_J)U77+J[SE&?$?^X.!^@S^--"
M97TV6V@U*VFO%=[>.0,ZH`2P'.,&O2D\?Z(R@DW"D_PF+D?D:\\M=!U6^MUN
M+:QFEA;.UU'!QQ4W_"+:Y_T#)_R%`CO_`/A/M#_YZ3_]^C7->,==TG7+2W:U
M>3[3"YQNC(!4]?Y"L7_A%M<_Z!D_Y"C_`(1;7/\`H&3_`)"@-3(HJ2>"6VG>
M">-HY4.UE88(-1TQ'2^!]2-AXACB8XBNAY39/?JI^N>/QKUBO`T=HW5U.&4Y
M!]#7MNC:BNK:1;7J]9$^8>C#@C\P:3*1?HHHI#"BBB@#FO&^E?VCH331INGM
M3YBXZ[?XA^7/X5Y/7OC*'4JP!4C!!'!%>+>(-+.D:U<6@!$8;=$3W0\C_#\*
M:$S,K;\*:K_9.O02N<0R_NI?8'O^!P:Q**9)[[7!_$?4=L5KIJ$Y8^<_/;D*
M/SS^0K?\)ZL-4\/PR2-F6']U*6]0.OXC!_.O,O$&I?VMKES=@_NRVV/_`'1P
M/\?QI(IF[\/M-^TZO)?.I,=LGRGMO;C\>,_I7IM87A#3?[-\.VZLN)9AYTGX
M]!^6*W:0(****!A1110!C^*=2_LOP_<S*P65QY47^\W''T&3^%>-5VWQ$U+S
M;^#3D8%8%\R0#^\>@/X<_P#`JY2QTR]U)G6SMGF*`%M@Z4T2SN]%\9Z)I^E6
M]EMN8_)C"DF(89NI(P3WR?QK0_X3[0_^>D__`'Z-<!_PBVN?]`R?\A1_PBVN
M?]`R?\A0%V=EJ_B_0=3TFZLR\V98R%S%T;J#^>*\VK7_`.$6US_H&3_D*IWV
MF7NFLBWEL\)<$KO'6@"I4UI=265Y#=0G$D3AU_`U#13$>[VES'>6<-S$<QRH
M'7Z$9J:N.^'NJ?:=*DL';]Y;-E/]QN?YY_,5V-26%%%%`!1110`4444`%%%9
M/B'7(M"TUKAL-,WRPQG^)O\``=__`*]`'-_$/4;,VT6G[%DNPPD#`_ZH?_7]
M/Q]*\\JTQN]6U'/SSW5P_P"+$_Y_"NPUKP,+30(I[0F2\@7,X!SY@[X^G\O>
MF3N<+1113$>K^#?$/]L6'V>X;-Y;@!B?XUZ!OKZ__7KIJ\,TW4)]+U"&\MSB
M2)LX/1AW!]B*]ITW4(-4T^&\MSF.5<X/53W!]P:3*3+5%%%(84444`%%%%`!
M1110`4444`%%%%`!1110!D>*?^17U#_KD?YUXS7LGBQU3PMJ!8X'EX_$D`5X
MW31+"BBBF(]+^'$H.C746.5N-V?JH']*[*O,?A]J26NL2V<AP+M`%/\`M+D@
M?D37IU2RD%%%%`PHHHH`*CN)X[6VDN)FVQQJ78^@%2$@`DG`'4FO-O&?BI+_
M`/XEVGR[K8<RR+T<^@]J`.7U6_?5-5N;U^LKY`]!T`_``53HHJB`KI?!>BG5
M-96>1<VUJ1(^?XF_A'YC/T%8NF:=<:K?Q6ELFYW/)[*.['V%>R:1I<&C:;%9
MP<A>68]78]328TB]1112*"BBB@`HHHH`****`/"K[_D(7/\`UU;^9JO5B^_Y
M"%S_`-=6_F:KU1`5[XB+&BHHPJC`'H*\#KWVDRD%%%%(84444`%%%%`!1110
M!R'Q&_Y%ZW_Z^E_]`>N(\+D#Q/I^3C]\*[?XC?\`(O6__7TO_H#UP.A?\C#I
MO_7U%_Z&*:)>Y[;1112*"BBB@`K-UK1;77+$V]P,,.8Y0/F0^H_J*TJ*`/$-
M5TJZT>^:UNDPPY5A]UQZBJ->UZUHMKKEB;>X&&',<H'S(?4?U%>1:KI5UH]\
MUK=)AARK#[KCU%,EHHUI:+K5UH=\+BW.5/$D9/RN/0_T-9M%,1K^)KZWU/6Y
M+ZV9BDZ(Q5A@J0H!'Z5WGP_D5_#6T=4G=3]>#_45Y97IWPY_Y%ZX_P"OIO\`
MT!*3&CKZ***104444`8/C'4O[-\.SE6*S3_N8\>_7],_I7DD$,ES<101#=)*
MX11ZDG`KK/B#J7VG5X[%&)CMD^8=M[<_CQC]:A\`Z=]LU[[2P/EVB;^G!8\`
M?S/X4R7N>EV-I'86$%I%]R%`@/KCO5BBBD4%%%%`'FWQ#TSR-2AU%!\EPNQ_
M]]>GYC'_`'R:XNO9O$^F?VMH%S;JFZ91YD7'.X=A]1D?C7C--$L*[WX<ZGA[
MG3';@_OHOKT8?R_(UP57]&U`Z7K%K>`G;&XW@=U/!'Y9I@CVZBD5@ZAE(*D9
M!!X(I:DH****`"N,^(6E?:-.BU*,?O+<[']T)_H?YFNSJ*YMX[NUEMY1F.5"
MC#V(Q0!X/15G4+*33=0GLY>7A<J2._H?Q'-5JH@T],UJXTRRU"VB^[>1;"?[
MISU_(L/Q'I2^'=,_M;7;:U(S'NWR_P"X.3^?3\:RZ]$^'.F^7:W.I.OS2'RH
MR?[HY/ZX_*D-'<T444B@HHHH`*9-,EO!)-(VV.-2['T`&33ZY;QYJ7V+0?LR
M-B2[;9[[1RW]!^-`'FFHWCZAJ-Q>2?>FD+X]!V'X#BO3/`FF_8M`%PZ@2W;>
M83WVCA1_,_C7F>GVCW^HV]HG#32!,^F3UKW&&%+>".&-=L<:A%'H`,"FQ(?1
M112&%<SXYTS[?X?>95S+:GS1C^[_`!?IS^%=-2.BR(R,,JPP1ZB@#P.BKVLZ
M>VE:O<V;=(W.T^JGD'\L51JB#9\+:G_97B"WF9L1.?*D_P!UO\#@_A7LE>!5
M[/X9U+^U=`M;AF+2A?+E)Z[AP3^/7\:3*1K4444AA1110`444$@`DG`'4F@"
M"\O(+"TENKF01PQC+,:\<UW6I]<U)[J7Y4'RQ1YR$7_'UK5\8^)?[8NA:VK'
M[%">#_ST;^]]/2CP?X:.L7?VJY3_`$&%N0?^6C?W?IZTR7J=#X%\._8[<:I=
M)B>4?N5/5$/?ZG^7UKM*````!@#H!12*/+?&GAS^RKO[;;)BSG;D#_EF_I]#
MR?TKE*]WN[2&^M);6X3?#*NUEKQG6](GT34I+2;E>L;XX=>QIHEHSJZ?P9K_
M`/9.H_9IWQ:7!`;/\#=F_H?_`*U<Q13`]]HKD/`VO_;[+^SKA\W-NOR$_P`<
M?^(Z?3'O77U)04444`%%%%`!1110`4444`%%%%`!4<]Q!:Q&2XFCBC'\4C!1
M^9KS'Q1XCU=-;O+2*^EB@BDVHL7R$#CN.?UKEY9I9WWS2O(W]YV)/ZT["N=M
MXS\56M_:?V;I\AD0L&EE&0IQ_"/7G!KAJ**8@HHHH$*CM&ZNC%64Y#`X(/K7
MH.@^/XV1;?6!M<8`N$&0?]X=C[C\A7GM%`SW6UOK2^0/:W,4RXS^[<''U]*L
M5X%5C[=>?\_4_P#W\-*P[GNC,$4LQ`4#))/`%8NI^+-(TL$/=+-+CB*#YS^)
MZ#\37D$LTLQ!EE>0CH68G%,HL%SH]=\8W^LJT$?^BVIX,:'EQ_M'O].E<Y14
MUK:7-[,(;6"2:0_PHI)IB(:T-(T6]UJZ$%I'D#[\AX5!ZD_TZUU&C?#Z>4K-
MJTGE1]?)C.6/U/0?K^%=]:6=M86ZV]K"D42]%44KA8HZ%H%IH-H8H/GE?F29
MA\S_`.`]JU:**104444`%%%%`!1110`45Q=U\1[&/(M;*>8CNY"`_P`_Y5BW
M7Q$U27(MX+>`'O@LP_/C]*+"N<Q??\A"Y_ZZM_,U7ITCM+(TCG+,2Q/J33:H
MD*]]KP*NRLOB'>6T$44UE!*(U"Y5BI(`Q[\TF-'I=%<1;?$BTD=1<V$L()P6
M1P^!Z]!7;TB@HHHH`****`"BL;Q!XBM_#\4#31/*TS$*JD#@=3^HK!_X639_
M]`^?_OL4!<F^(\BC0[6/^)KD,/H%;/\`,5YW8R>5J%M)OV;)5;=G&,$<YK9\
M3^*&\0&&-+?R((22`6W%B>Y]/I7/4R6>^T5YO9_$:[AA2.YL8YRJ[2RR%2Q]
M3D&M!/B3:D+YFG3*>X60''\J5AW.XHJ&TN4O+."ZC#!)HUD4-U`(R,_G4U`P
MHHHH`*S=:T6UURQ-O<###F.4#YD/J/ZBM*B@#Q#5=*NM'OFM;I,,.58?=<>H
MJC7M>M:+:ZY8FWN!AAS'*!\R'U']17D6JZ5=:/?-:W288<JP^ZX]13):*->G
M?#G_`)%ZX_Z^F_\`0$KS&O3OAS_R+UQ_U]-_Z`E#!'7T45#=W*6=G/=2!BD,
M;2,%ZD`9./RI%$U5[Z\BT^QFNYCB.)"Q]_:N&NOB3(<BTTY5]&EDS^@`_G7-
M:QXEU+7%$=U(BPJ=PBC7"Y]?4_B:=A7,Z[N9+R\FN93F25R[?4G->G>`;-;?
MPXMP`-]S(S$]\`[0/T/YUY76UH_BG4]$C\FVD1X,D^5*NY0?;H1^=`D>QT5Y
M]!\2I!@7&FHW(R8Y2,#OP0?YUZ#2*"BBLC7]?@\/VT4LT,DOFMM4)@?GF@#7
MKQSQ7IG]E>(;B)1B*0^='_NMV_`Y'X5M7?Q'OI!BTLX(,]W8R'^@_2N5U#4;
MK5+IKF\E,DI&,D8P/0`4T2V5:***8CU7P+JPO]$%J[?OK3"')ZI_"?Z?A745
MX;IVIWFDW/VBRF,4F,'@$$>A!X-=1;?$?44(^TV=M*H'.S*$_CDC]*5BDSTJ
MBJNFWRZEIT%XB%%F7<%)Y%6J0PHHHH`\Z^(NF^7=V^I(IVRCRI#VW#I^8S_W
MS7#U[1XCTT:KH-U;`9DV[X\#)WCD?GT_&O%Z:)8^&%[B>.&-=TDC!%`[DG`K
MW#3K&+3-.@LH?N0H%SZGN?Q.3^->9>!=/^V^(TE89CME,ISZ]!^IS^%>KT,:
M"BBBD,***X_6O'D>F7T]G#8O+)$=I9W"C/X`Y_2@#L*\E\:ZHNI>('6)@T-L
MOE*0>">I/YG'X5)J'CK5[Z)XHS%;1L,'RE.['U/],5S%-$MG8?#NT2;6YKEL
M$P1?*/=N,_EG\Z]-KP[3=4O-(NOM%E+Y;XP>`0P]"#756_Q(O4"BXL8)<==C
M%,_GFAC3/1Z*S="U==;TQ+U83%EBI0MG!'O6E2&%%5[Z\BT^QFNYMWEPH68*
M,D^PKAKKXDR'(M-.5?1I9,_H`/YT!<7XCZ:`;74D`!8^3)[GDK_[-^E<%6KK
M'B/4M;"K=RKY2MN6)%PH/\S^)K*IDL*[+X?:L+74I-.E;$=R,QY/1QV_$?R%
M<;2H[1NKHQ5E.0P."#ZTP/?**\MM/B!K$"JLRV]P!U+H0Q_$$#]*[7PUXD7Q
M%#.?LY@D@*[EW;@<YP0<#T-2.YNT45Q4WQ(L%SY%C<OQQO*KS^&:!G:UY[XU
M\5>89=(L6^0?+/*#][_9'MZ_E]<_5?'NHW\+0VT:6<;`@E#N?'^]V_`5RE.P
MFR>RM)+^]AM(?]9*X09[9[U[=864.G6,-I`N(XEVCW]3]2>:\+1VC=71BK*<
MA@<$'UKK-.^(&J6H5+N..[0#&6^1_P`QQ^E#$CU"BL30O%%EKSO%`DD<R+N9
M)`.G3((//6MND4%8'BS0EUK26,:9NX`7B(')]5_'^>*IZGX]L+"YGMH[:>:>
M%V1NBKD9!YZ]1Z5@7?Q&U"566UM((,]&8ER/Y#]*8KG&44K,68L3DDY-)3))
M[.[FL+R*ZMVVRQ-N4U[)H>LV^N:<ES"<..)8^Z-W'T]#7BE7M+U>]T>X,]E,
M48C#*>58>XI#3/;Z*\_L_B2V`+[3P3W>!\?^.G_&NXL;R+4+&&[AW>7,@90P
MP1[&D5<L4444`%%%%`!1110`4444`<S?^!M,U&_FO)I[M9)6W,$=0`?;*U77
MX=:.&!,]ZP!Z&1<'_P`=KKJ*`L<TG@/0D<,T$K@?PM*<'\L5-_PA7A[_`*!_
M_D:3_P"*K?HH"Q@?\(5X>_Z!_P#Y&D_^*H_X0KP]_P!`_P#\C2?_`!5;]%`&
M!_PA7A[_`*!__D:3_P"*I#X)\/$$?8,>XFD_^*KH**`.8_X0'0_^><__`']-
M0O\`#O1G<LLUX@/\*R+@?FIKK:*`L<A_PKG2/^?F^_[[3_XFGQ_#S1D;+27<
M@QT:08_117644!8P[;P?H5L05L$D8=Y6+Y_`G'Z5L0P0VT8C@B2)!T5%"C\A
M4E%`!1110`4444`%%%%`!1110`4C*'4JP!4C!!'!%+10!R'_``KG2/\`GYOO
M^^T_^)J6/X?:*BX8W4ASU:09_0"NJHH"QS'_``@.A_\`/.?_`+^FIQX)\/``
M?8,^YFD_^*KH**`L<T_@/0G<LL$J`_PK*<#\\U3D^'&EE?W=W>*WJQ5A^6T5
MV-%`6.,A^'=I#/'*+^8E&#`;!S@UV=%%`!1110`4444`87B7PVOB**W7[3Y#
M0LQ#>7OR#CCJ/05A1_#6`+^]U*1FSU6(*,?F:[JB@+''I\.=*"`/=7I;N0R@
M?EMI?^%<Z1_S\WW_`'VG_P`377T4"L<2_P`-[(EO+O[A1V#*IQ_*J_\`PK/_
M`*B__DM_]G7?447"Q7L;;[%I]M:;]_D1+'NQC=M`&<?A5BBB@84444`%%%%`
M!65K^A6^O6'D2G9*F6BD'\!_J/:M6B@#R-_!'B!7918A@#@,)DP??DYKN?!>
MEWFDZ/-!?0^5*UPSA=P;C:HSP3Z&NCHHN*P5#=VR7EG/:R%@DT;1L5Z@$8./
MSJ:B@9R'_"N=(_Y^;[_OM/\`XFKL'@?086W&U>4Y!'F2M@?@"/UKHJ*`L83^
M#?#\CEFTY03_`'9'4?D#4,O@;0)``MH\>.Z3-S^9-='10%CF/^$!T/\`YYS_
M`/?TUT]%%`!65K>@6NO0Q174DR+$Q9?*(!S^(-:M%`'+CP#H8`&R<^_FU+%X
M%T"/.ZUDDS_?F;C\B*Z.B@+&!_PA7A[_`*!__D:3_P"*I&\$^'RI`L"I(ZB9
M\C_QZN@HH`Y9_A_HCH547*$_Q+)R/S!J'_A7.D?\_-]_WVG_`,377T4!8J:9
MI\.E:?#96Y<Q1`X+G).22<_B:MT44`%%%%`!7`ZA\/9KG4;B>"\BCBED+JC*
M25R<XKOJ*`,'POX=_P"$?M9U>999IG!9E&``!P/U/YUO444`%%%%`!7,7_@;
M3-1OIKR:XO!),Q9@KJ`/I\M=/10!R\/@#0XL;UN)L'^.7&?^^0*N-X.T!D5#
MIR87IB1P?Q.<FMRB@+'/MX)\/E2!8%21U$SY'_CU0?\`"`Z'_P`\Y_\`OZ:Z
M>B@+%/3-,MM)LEM+166($M\S9.35RBB@"M?V4>HV$UG,SK'*NUBA`('MFN>C
M^'^B(N&^TR'^\TG/Z`5U5%`',IX#T)6!,,S`?PF4X/Y5/_PA7A[_`*!__D:3
M_P"*K?HH"Q@?\(5X>_Z!_P#Y&D_^*J!_`>A,Q(AF4'^$2G`_.NFHH"QR)^'6
MCDD_:+T>V]/_`(FM?0_#EGX?\_[))._G[=WFL#C;G&,`>IK7HH`*XC_A6UG_
M`-!"?_O@5V]%`'')\.-+"`275XS=RK*!^6TU/'\/M%1<,;J0YZM(,_H!7544
M"L<L_P`/]$="JBY0G^)9.1^8-5I/AQIA7]U=W:MGJQ5AC\A7944#L<[H'A*W
MT&]DNHKF65GC,>&```)!_I71444`<M=^`M+O+R>ZDN+P/-(TC!77`).3CY?>
MH?\`A7.D?\_-]_WVG_Q-=?10%CEQX!T,`#9.??S:L#P3X>``^P9]S-)_\570
M44!8YB3P#H;[ML<Z9SC;*?E^F<_K55_AQI90B.ZO%;L692/RVBNQHH"QQ'_"
MMK/_`*"$_P#WP*["RM5L;"WM$.Y88UC!(QG`QFIZ*`"BBB@`HHHH`****`"B
MBLCQ1KG_``C?AVZU;[/]H^S[/W6_9NW.J]<''WL]*<8N345NQ2DHIR>R->BO
M(O\`A>'_`%+O_D[_`/:Z/^%X?]2[_P"3O_VNNOZAB/Y?Q7^9R_7L/_-^#_R/
M7:*\B_X7A_U+O_D[_P#:Z/\`A>'_`%+O_D[_`/:Z/J&(_E_%?YA]>P_\WX/_
M`"/7:*\B_P"%X?\`4N_^3O\`]KH_X7A_U+O_`).__:Z/J&(_E_%?YA]>P_\`
M-^#_`,CUVBO(O^%X?]2[_P"3O_VNC_A>'_4N_P#D[_\`:Z/J&(_E_%?YA]>P
M_P#-^#_R/7:*\B_X7A_U+O\`Y.__`&NC_A>'_4N_^3O_`-KH^H8C^7\5_F'U
M[#_S?@_\CUVBO(O^%X?]2[_Y._\`VNC_`(7A_P!2[_Y._P#VNCZAB/Y?Q7^8
M?7L/_-^#_P`CUVBO(O\`A>'_`%+O_D[_`/:Z/^%X?]2[_P"3O_VNCZAB/Y?Q
M7^8?7L/_`#?@_P#(]=HKR+_A>'_4N_\`D[_]KH_X7A_U+O\`Y.__`&NCZAB/
MY?Q7^8?7L/\`S?@_\CUVBO(O^%X?]2[_`.3O_P!KH_X7A_U+O_D[_P#:Z/J&
M(_E_%?YA]>P_\WX/_(]=HKR+_A>'_4N_^3O_`-KH_P"%X?\`4N_^3O\`]KH^
MH8C^7\5_F'U[#_S?@_\`(]=HKR+_`(7A_P!2[_Y._P#VNC_A>'_4N_\`D[_]
MKH^H8C^7\5_F'U[#_P`WX/\`R/7:*\B_X7A_U+O_`).__:Z/^%X?]2[_`.3O
M_P!KH^H8C^7\5_F'U[#_`,WX/_(]=HKR+_A>'_4N_P#D[_\`:Z/^%X?]2[_Y
M._\`VNCZAB/Y?Q7^8?7L/_-^#_R/7:*\B_X7A_U+O_D[_P#:Z/\`A>'_`%+O
M_D[_`/:Z/J&(_E_%?YA]>P_\WX/_`"/7:*\B_P"%X?\`4N_^3O\`]KH_X7A_
MU+O_`).__:Z/J&(_E_%?YA]>P_\`-^#_`,CUVBO(O^%X?]2[_P"3O_VNC_A>
M'_4N_P#D[_\`:Z/J&(_E_%?YA]>P_P#-^#_R/7:*\B_X7A_U+O\`Y.__`&NC
M_A>'_4N_^3O_`-KH^H8C^7\5_F'U[#_S?@_\CUVBO(O^%X?]2[_Y._\`VNC_
M`(7A_P!2[_Y._P#VNCZAB/Y?Q7^8?7L/_-^#_P`CUVBO(O\`A>'_`%+O_D[_
M`/:Z/^%X?]2[_P"3O_VNCZAB/Y?Q7^8?7L/_`#?@_P#(]=HKR+_A>'_4N_\`
MD[_]KH_X7A_U+O\`Y.__`&NCZAB/Y?Q7^8?7L/\`S?@_\CUVBO(O^%X?]2[_
M`.3O_P!KH_X7A_U+O_D[_P#:Z/J&(_E_%?YA]>P_\WX/_(]=HKR+_A>'_4N_
M^3O_`-KH_P"%X?\`4N_^3O\`]KH^H8C^7\5_F'U[#_S?@_\`(]=HKR+_`(7A
M_P!2[_Y._P#VNC_A>'_4N_\`D[_]KH^H8C^7\5_F'U[#_P`WX/\`R/7:*\B_
MX7A_U+O_`).__:Z/^%X?]2[_`.3O_P!KH^H8C^7\5_F'U[#_`,WX/_(]=HKR
M+_A>'_4N_P#D[_\`:Z/^%X?]2[_Y._\`VNCZAB/Y?Q7^8?7L/_-^#_R/7:*\
MB_X7A_U+O_D[_P#:Z/\`A>'_`%+O_D[_`/:Z/J&(_E_%?YA]>P_\WX/_`"/7
M:*\B_P"%X?\`4N_^3O\`]KH_X7A_U+O_`).__:Z/J&(_E_%?YA]>P_\`-^#_
M`,CUVBO(O^%X?]2[_P"3O_VNC_A>'_4N_P#D[_\`:Z/J&(_E_%?YA]>P_P#-
M^#_R/7:*\B_X7A_U+O\`Y.__`&NC_A>'_4N_^3O_`-KH^H8C^7\5_F'U[#_S
M?@_\CUVBO(O^%X?]2[_Y._\`VNC_`(7A_P!2[_Y._P#VNCZAB/Y?Q7^8?7L/
M_-^#_P`CUVBO(O\`A>'_`%+O_D[_`/:Z/^%X?]2[_P"3O_VNCZAB/Y?Q7^8?
M7L/_`#?@_P#(]=HKR+_A>'_4N_\`D[_]KH_X7A_U+O\`Y.__`&NCZAB/Y?Q7
M^8?7L/\`S?@_\CUVBO(O^%X?]2[_`.3O_P!KH_X7A_U+O_D[_P#:Z/J&(_E_
M%?YA]>P_\WX/_(]=HKR+_A>'_4N_^3O_`-KH_P"%X?\`4N_^3O\`]KH^H8C^
M7\5_F'U[#_S?@_\`(]=HKR+_`(7A_P!2[_Y._P#VNC_A>'_4N_\`D[_]KH^H
M8C^7\5_F'U[#_P`WX/\`R/7:*\B_X7A_U+O_`).__:Z/^%X?]2[_`.3O_P!K
MH^H8C^7\5_F'U[#_`,WX/_(]=HKR+_A>'_4N_P#D[_\`:Z/^%X?]2[_Y._\`
MVNCZAB/Y?Q7^8?7L/_-^#_R/7:*\B_X7A_U+O_D[_P#:Z/\`A>'_`%+O_D[_
M`/:Z/J&(_E_%?YA]>P_\WX/_`"/7:*\B_P"%X?\`4N_^3O\`]KH_X7A_U+O_
M`).__:Z/J&(_E_%?YA]>P_\`-^#_`,CUVBO(O^%X?]2[_P"3O_VNC_A>'_4N
M_P#D[_\`:Z/J&(_E_%?YA]>P_P#-^#_R/7:*\B_X7A_U+O\`Y.__`&NC_A>'
M_4N_^3O_`-KH^H8C^7\5_F'U[#_S?@_\CUVBO(O^%X?]2[_Y._\`VNC_`(7A
M_P!2[_Y._P#VNCZAB/Y?Q7^8?7L/_-^#_P`CUVBO(O\`A>'_`%+O_D[_`/:Z
M/^%X?]2[_P"3O_VNCZAB/Y?Q7^8?7L/_`#?@_P#(]=HKR+_A>'_4N_\`D[_]
MKH_X7A_U+O\`Y.__`&NCZAB/Y?Q7^8?7L/\`S?@_\CUVBO(O^%X?]2[_`.3O
M_P!KH_X7A_U+O_D[_P#:Z/J&(_E_%?YA]>P_\WX/_(]=HKR+_A>'_4N_^3O_
M`-KH_P"%X?\`4N_^3O\`]KH^H8C^7\5_F'U[#_S?@_\`(]=HKR+_`(7A_P!2
M[_Y._P#VNC_A>'_4N_\`D[_]KH^H8C^7\5_F'U[#_P`WX/\`R/7:*\B_X7A_
MU+O_`).__:Z/^%X?]2[_`.3O_P!KH^H8C^7\5_F'U[#_`,WX/_(]=HKR+_A>
M'_4N_P#D[_\`:Z/^%X?]2[_Y._\`VNCZAB/Y?Q7^8?7L/_-^#_R/7:*\B_X7
MA_U+O_D[_P#:Z/\`A>'_`%+O_D[_`/:Z/J&(_E_%?YA]>P_\WX/_`"/7:*\B
M_P"%X?\`4N_^3O\`]KH_X7A_U+O_`).__:Z/J&(_E_%?YA]>P_\`-^#_`,CU
MVBO(O^%X?]2[_P"3O_VNC_A>'_4N_P#D[_\`:Z/J&(_E_%?YA]>P_P#-^#_R
M/7:*\B_X7A_U+O\`Y.__`&NC_A>'_4N_^3O_`-KH^H8C^7\5_F'U[#_S?@_\
MCUVBO(O^%X?]2[_Y._\`VNC_`(7A_P!2[_Y._P#VNCZAB/Y?Q7^8?7L/_-^#
M_P`CUVBO(O\`A>'_`%+O_D[_`/:Z],T#5?[<T*SU/R?(^TQ[_+W;MOMG`S^5
M95<-5I*\U8UI8BG5=H.YHT445@;!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`>?
M?$3QUJGA*_LH+""SD2>(NQG1B00<<885QG_"Z/$?_/EI7_?J3_XNK?QL_P"0
MSI?_`%[M_P"A54^%?A?1O$G]K?VM9_:/L_D^5^]=-N[?G[I&?NCK7LTJ=".&
M56<;_P##GCU:E:6)=*$K?\,7;'XV7ZNHU#2;:5,_,;=V0X]@=W^?2O4/#WB7
M3/$]A]KTV8N%P)(W&'C)'1A_49'H:\U^('PTL=,TB35]"CDB6#!GMBY==G=E
M)R<COD]/3'/%>!_$4OAOQ/;7`<"VE80W(8X7RR>3]1U_"IEAJ->DYT59HJ.(
MK4*BA6=T?2U%%%>0>L>3^+OB-XG\+^([C3FLM,:$'S+=VBD)>,_=)^<<]0>.
MH-=#\/?'3^+8KJ"^2WAOX#O"0@@/&>,@$D\'@_45%\4_#*ZUX<:_@CS>Z>#(
M".K1_P`:_P!?P/K7B_AK7)?#OB"TU.+)$3_O$'\:'AE_+./?!KUZ5"EB,/[J
MM)?G_P`$\JI6J4,1[SO%_P!?@?0_B_Q$GA?PY<:B0C3#$=O&_1Y#T!]AR3[`
MUP_@[XA>)_%7B&&P%IIB6Z_O+B18I,K&#SCY^IS@?6N6^*'BN+Q#K4-K8SB7
M3[1/E=3Q([`%F_`8'X'UKT?X8>&/[!\-K=3KB]OPLK@CE$_@7\CD^YQVK)T8
M4<-S37O/8T56=;$<L'[J.WHHHKS3T3Q*]^,/B&VO[B!+/3"L4K("8I,X!(_O
MUWO@#QH?%VFS&Z6&+4('Q)'%D`H>C`$D^H//;WKP#5?^0Q??]?$G_H1K1\)>
M(9?#/B*VU!"?*SY<Z#^.,D;A^@(]P*]ZM@J<J7N*S/"I8RI&K[[NCW+X@^)[
MWPIH,%_816\DLETL)$ZL5VE7/8CGY14'P[\6W_BVPO9[^&VC:"5440*P!!&>
M<L:R?C#/%<^!]/G@D62*6]C='4Y#*8Y""/;%5_@G_P`@?5?^OA/_`$&N!4H?
M5'.VMSN=67UM0OI8]1HHHK@.\1W6-&=V"HHRS$X`'K7A\_QHUW[1)Y%CIPAW
M'RQ)&Y;;GC.'QG%>B_$G5_['\$7K(Q66ZQ:QD>K_`'O_`!T-7SO':3S6L]S'
M&3#!M$CY'R[C@?G@UZN7X>$XN=17/+Q^(G"2A!GT#\._&5SXNL+U[Z*WCN;:
M51M@4A=C#C@D\Y#5V=?/WPGU4Z?XUBMF($5[&T+9[$#<I^N5Q^-?0-<N-HJE
M5:CLSIP=5U:5WN@KF_'.MZCX=\-2:IIL5O(\,B"43J2-C';Q@@YW%?UKI*HZ
MSIR:OHM[I[XQ<PM'DG&"1P?P.#7/3:4TY;'143<&H[GEGA[XN:MJ'B&PLM0M
M-/2UN)EB=HD=6!;@')8CJ1VZ5[#7R21+;7!!W1RQ-C@X*L#_`#S7U/HNHKJ^
MAV.HJ`/M,"2$#H"1R/P.17?F&'A3Y905DSAP%>53FC-W9P?C[XD7_AG7TTW3
M8+.4+"KS-.KL58DX'##M@]^M=7X+UC4=?\,P:GJ4,,4L[,46%64;`<`X))YP
M3],5\_Z_>R>(_%]Y<1?.UW=;(1DG*YVH/RQ7TMIEC'IFEVEA$<I;0I$IQC(4
M`9_2EBZ4*5&$;>\QX6K.K5E*_NHM4445YQZ!P_Q$\;W7A&.P2PBMY;FY+EA.
M"P5%QV#`Y)/'T-<59?&76WO[9+NTTU;9I5$S)&X8)D;L$N><9K#^)VK_`-K>
M-[M58F*SQ:H/0K][_P`>+?I7*7=I/8W3VUS&8YH^&0D''&>U>]A\'2]DN=:L
M\/$8NI[5\CT1]:45S?@+53K'@K3;ER#*D?DR?5#MR?<@`_C725X<XN$G%]#V
MH24XJ2ZA7GWQ`\8^(?"-[;O:6EC+I]PN%DEC<LKCJI(8#IR/Q]*]!K(\3Z#!
MXDT"YTV;`9US$Y_@D'W6_/K[9K2A*$:B<U=$5HRE!J#LSAO!'Q0O-?\`$"Z9
MJT%G")D/D/`K+EQS@[F/49_'`[UU_C3Q.GA7P_+>@1O=,0EO$_1W/J!S@#D_
M_7KYQD2\T;5F0[H+RSFZCJCJ>H_$5L^,/%]UXNO+6:=!%';PA%C'3>0-[?B?
MT`KU9X",JL91^'K_`%YGE0QTHTI1E\73^O(]`\'_`!#\3^*?$,%@++35MQ^\
MN)%B?*1CKC+]3P!UY/I7JU<=\./"O_"-^'5>XCVZA>8EFW+AD&/E3\/YDUV-
M>9BI4W4:IJR1Z6&C-4TZCNV%%%%<YT!1110!D^)M4GT7PU?ZE;+&TUO%O19`
M2I.>^"#^M>0_\+H\1_\`/EI7_?J3_P"+KVG4].M]7TVXT^Z#&"==CA3@X^M<
M!KWPO\-:?X>U.]@BN1-;VDLL9,Q(W*A(X^HKNPDZ"7+55VV<6*A7;YJ;LK'*
M_P#"Z/$?_/EI7_?J3_XNC_A='B/_`)\M*_[]2?\`Q=<#80I<:C;0R9V22JC8
M]"0*]X_X5'X5_P">5U_W_-=]>.%H64X[G#0EBJU^66QW5%%%>$>V>7^.?B/K
M'AGQ*^FV5M8R0K$CAID<MDCV8#]*YO\`X71XC_Y\M*_[]2?_`!=4_BY_R/<O
M_7O'_*MWX8^#=`\0^&[B[U6P^T3I>-$K>=(F%"(<85@.I->TJ>'IX>-2<;['
MC.=>I7E3A*VYG?\`"Z/$?_/EI7_?J3_XNO0?AWXMO_%MA>SW\-M&T$JHH@5@
M"",\Y8U+_P`*P\'?]`?_`,F9O_BZVM$\.:3X<AEATJU^SI*P9QYC/DCC^(FN
M2O6PTH-4XV?]>9UT*6(C-.I*Z_KR-2BBL'QGK3:!X2O]0C8"=4V0^N]B%!'K
MC.?PKBA%RDHKJ=DI*,7)]#G_`!A\3['P[<R:?8PB]OTX?YL1Q'T)')(]!^>:
MX"7XO^*))"RFRB!_@2#@?F2?UKB((9[^^CACW2W%Q($7/)9F.!^))KZ!L?AA
MX9M](2SN;`7,VT>9<,[!V;N001@>P_7G/L3IX;"Q2FKMGDPJ8C%2;@[)'.^&
MOC"EY>1VNNVL-L)#M%U"2$4]MRG)`]\UZH"&4,I!!Y!'>OESQ-HQ\/\`B2^T
MO<66"3",V,E"`RDX[X(KW/X8ZN^K>"+7S6+RVC-;,Q[[<%?_`!UE%88W#0C!
M5:>S-L'B9RFZ53='8UD^)M4GT7PU?ZE;+&TUO%O19`2I.>^"#^M:U<YX]_Y$
M36/^O<_S%<%))SBGW1WU6U!M=CSS1/BWKVI:]IUA-:::L5S=10N4CD#!68`X
MR_7FO9J^7/"G_(XZ)_V$(/\`T8M?4==F84H4Y14%8X\!5G4BW-W/&=;^+>O:
M;KVHV$-IIK16UU+"A>.0L55B!G#]>*]0\,ZI/K7AJPU*Y6-9KB+>ZQ@A0<]L
MDG]:^<O%?_(XZW_V$)__`$8U?0'@+_D1-'_Z]Q_,UIC:-.%&,HJS_P"`9X.M
M.=649.Z_X)T=9/B;5)]%\-7^I6RQM-;Q;T60$J3GO@@_K6M7.>/?^1$UC_KW
M/\Q7GTDG.*?='H56U!M=CR[_`(71XC_Y\M*_[]2?_%U[#X?UJ#Q!H=KJ5N1B
M9`74'.Q_XE/T-?+%>C?"3Q/_`&9K3:-<RA;2^.8]QX6;@#_OH#'UVUZ^,P</
M9\U-6:/(PF,G[3EJ.Z9U?Q!^(.K>%->@L+"WLI(I+59B9T<MN+..S#CY179^
M&=4GUKPU8:E<K&LUQ%O=8P0H.>V23^M>0_&C_D<;3_L'I_Z,DKU'P%_R(FC_
M`/7N/YFN.O2A'#0FEJSLHU)RQ,XMZ(Z.BBL+QEK1T#PGJ&H(<3+'LAY&=[':
MI]\$Y^@-<48N4E%=3LE)1BY/H<YXR^)]KX=NFT_3X$O;Y.)"6Q'$?0XY)]AC
M'KVK@S\7_%!G\P?8@N<^6(#M^G7./QKC=/L[C6-6M[.(E[BZF"!FR>6/4_S)
MKWQ/A=X572Q9-8LSX&;GS&\PMC[V<X'TQCVKV)PPV%2C-7;/)A/$XEN4'9(R
M?!_Q6@UN\CT_5X(K.ZDXCE1CY3MV7!Y4GMR<UZ17RKK6FRZ'KMYISD[[:8H&
MZ$@'Y6_$8/XU]$>!M:?7O!]A>3.7N`IBF8]2ZG&3[D`'\:YL;AH02J4]F=&"
MQ,YMTZFZ.BK)\3:I/HOAJ_U*V6-IK>+>BR`E2<]\$']:UJYSQ[_R(FL?]>Y_
MF*XJ23G%/NCMJMJ#:['GFB?%O7M2U[3K":TTU8KFZBA<I'(&"LP!QE^O->S5
M\N>%/^1QT3_L(0?^C%KZCKLS"E"G**@K''@*LZD6YNX4445YYWA7G_C+XGVO
MAVZ;3]/@2]ODXD);$<1]#CDGV&,>O:NC\9:T=`\)ZAJ"'$RQ[(>1G>QVJ??!
M.?H#7S=I]G<:QJUO9Q$O<74P0,V3RQZG^9->C@<+&HG4J;(\_&XF5.T(;L[(
M_%_Q09_,'V(+G/EB`[?IUSC\:[3P?\5H-;O(]/U>"*SNI.(Y48^4[=EP>5)[
M<G-:R?"[PJNEBR:Q9GP,W/F-YA;'WLYP/IC'M7@^M:;+H>NWFG.3OMIB@;H2
M`?E;\1@_C733AA<2G&$;-'/.6)PS4IRNF?55%<[X&UI]>\'V%Y,Y>X"F*9CU
M+J<9/N0`?QKHJ\><7"3B^AZT)*<5)=0KS_QE\3[7P[=-I^GP)>WR<2$MB.(^
MAQR3[#&/7M71>,]:;0/"5_J$;`3JFR'UWL0H(]<9S^%?.&E:?-K.LVEA$V);
MJ98][<XR>6/TZUWX+"QJ)U*FR.'&XF5-JG3W9V)^+_B@S^8/L07.?+$!V_3K
MG'XUVOA#XK6^MWL>GZM!'9W4G$<J-^[=O3GE2>W)]*UH_AAX572ULGL"[A<&
MY,C"0MC[V<XSWQC'M7B.K^&-0T[7[S2X+:XNC!-Y2O'"QWYP5X`ZD$''O71"
M.%Q*<8JS1SSEBL.U*3NF?3]%8WA2ZOKSPMI\VI0S0WOE;9EG0H^Y25R0>><9
M_&MFO(E'E;78]>,N9)E#6[V33=!U&_A5&EMK669`X)4LJDC..W%>0V7QA\0W
M-_;P/9Z8%EE5"1%)G!(']^O5O%?_`")VM_\`8/G_`/1;5\SZ5_R&+'_KXC_]
M"%>E@*-.I"3DKGFXZM.$XJ+L?5]%%%>6>F<9\1/%M_X2L+*>PAMI&GE9&$ZL
M0`!GC#"O/O\`A='B/_GRTK_OU)_\771_&S_D#Z5_U\/_`.@UQ7PQT'3?$/B2
MXM-5MOM$"6;2JN]DPP=!G*D'H37L8:E16&]I.-SR<14K/$>SA*QI?\+H\1_\
M^6E?]^I/_BZZ3P-\1]8\3>)4TV]MK&.%HG<M"CAL@>[$?I71?\*P\'?]`?\`
M\F9O_BZO:1X(\.Z%?B]TW3_(N`I4/YTC<'KPS$5A4KX1P:C"S_KS-J='%*:<
MIZ?UY'0445!>3FVL;BX4!C%&S@'O@9KSDKGH/0X7QI\3[;P[<OIVFPI>7Z<2
M,S?NX3Z''+'U`(QZYXK@C\7O%)E+AK,*3G8(.![=<X_&N&EEDGF>:5R\DC%G
M8]23R37O6B>&_AYJNGPPZ?#979:/!W3'S^0>6&0P/![#VKVYTJ&%@N:/-YGC
M0JU\3-\LK>1F>%_B]#J-W'9:W:QVLDK!4N(2?+R3C#`\J/?)_#K7J%>-M\%K
MF36;@+J,4&F!_P!RQ!>4KC/(X'MG/;.*];TZS_L_3+6R,SS?9XEB\R3[S[1C
M)]^*X,6J%TZ+^1W85U[-55\RS1117&=84444`%%%%`!1110!XM\;/^0SI?\`
MU[M_Z%5SX'_\Q[_MW_\`:E4_C9_R&=+_`.O=O_0J/@[JVG:9_;7]H:A:VGF>
M1L^T3+'NQYF<9(SC(_.O9:;P%E_6IXZ:6.N_ZT/6M<$3>']2$^WRC:RA]QP-
MNPYS[8KY4KV;XB_$33I=$FTC1;H7,UT-DTT6=J1]QGN3TX[$^U>:^$=#D\0^
M)K.P5<QEP\QQP(UY;_#ZD5>`@Z-*4YZ$XZ:JU8PAJ?2]F9FL;<W&?/,:F3(Q
M\V.?UJ>BBO#9[2"OF_X@^&O^$:\3S11*!9W.9[<#^%2>5_`Y'TQ7TA7BWQL_
MY#.E_P#7NW_H5=^73:K<JV9P9A!.CS/='.?#KPT/$?BB)9XP]E:_OIP1D-C[
MJGZGMZ`U]&5Y%\#_`/F/?]N__M2O7:68S<JSB]D/+X*-%274****X3N/ES_F
M</\`M_\`_:E;/Q'\+_\`"-^)':",+87F9;<*,!>?F3\"?R(K&_YG#_M__P#:
ME?07C7PVOBCPW/9+@7*?O;9CVD`X'T/(_'/:O?KU_8U(-[-:GA4:'MJ<TMUL
M>%3^)FO/A_%H%RY:6TOEEMR1_P`LBD@(S[,1_P!]>U>B_!/_`)`^J_\`7PG_
M`*#7C$D;PRO%*C)(A*LK#!4CJ".QKV?X)_\`('U7_KX3_P!!HQL%'#RMU88*
M3E7C?HCU&BBD)"J68@`<DGM7@'NGB_QIU7SM6T_2D;Y;>(S.!_>8X'Y!?_'O
MRN^!O"HO_A;K&4)GU/=Y78'R_P#5_P#CX-><>)-3?Q!XIOK]`7^T3D1``Y*C
MY4&/7`%'_"*>(_\`H`:K_P"`<G^%?0*ART(T^;E>C_7\SP/;7K2J<MUM^GY&
M?9W4MC?6]Y`0)8)%E0GLRG(_45]66-W'?V%M>1?ZN>)94^C`$?SKY3N[*[T^
M<P7MK-;3``F.:,HV#WP>:]W^$NK'4/!JVKG,EC*T/3JI^93^I'X5CF=/FIJH
MNAMEL^6;@^IWE%%%>*>R?./Q)TK^RO'-^`"([HBZ3.>=_+=?]K=76^%_%/V3
MX/ZLC2`3V1:WBR0?];]W'K@LW'/W?2K?QJTDR66G:O&G,3M;RD#/#<KGT`(;
M_OJO(4NIDM);57(AE=7=0>"5#`?^A&O?I16)P\;]+?@>#5D\/7E;K?\`$ZWX
M7:2-4\;VKNFZ*S4W+<<9'"_^/$'\*^AZ\P^"^E>1HU_JC@;KF41)TX5!S],E
MO_'17I]>;F%3GK-=M#T<!3Y**??4*HZSJ*:1HM[J#XQ;0M)@C.2!P/Q.!5ZO
M-_C)J_V3PW;Z8C#S+V7+#_IFF"?_`![;^1KGH4_:5%#N=%>I[.FY=CR?PSIS
M>(/%UA9S$N+BX#3'N5'S/^@-=9\8]*^R>*8-05<)>P#<?5T^4_\`CNRN&L='
MU34T=[#3;R[5#AF@@:0*?0X'%37'AS7+2!Y[G1M1AA09>22U=54>I)&!7T,H
MKVJES;:6/`C)^R<>7?6YZ3\%-5.[4](8C&!=1C\E;_V2O7J^9O`VK'1?&6FW
M1.(VE$,G&?E?Y2?PSG\*^F:\C,:?+6YNYZV7U.:ER]@HHKG/&_B5?"_AR:\1
MD^UO^[MD;NY[X]`.?_UUQ0@YR48[L[)S4(N3V1Y!\5[K3[KQM-]B0^;%&L=T
MX/#R#T]P,`_3';GG?"]U867B?3KG5(C)9QS!I%]/0GU`."1W`Q5OP?X?F\5^
M)X+1][0[O.NY">0@///J>GU.:B\7>'I?#'B.XTY\F+_60/\`WXST/U'(/N#7
MTD.2*^KWUL?/3YY/V]M+GTZ"&4,I!!Y!'>EKSOX3>*/[5T0Z/<R`W=@H$>3R
M\/0?]\_=^FVO1*^=K4G2FX/H>_2J*I!374****S-`HHHH`*R/%?_`")VM_\`
M8/G_`/1;5KUD>*_^1.UO_L'S_P#HMJNG\:]2*GP,^9]*_P"0Q8_]?$?_`*$*
M^KZ^4-*_Y#%C_P!?$?\`Z$*^KZ]/-=X_,\[+-I?(****\D]0^?\`XN?\CW+_
M`->\?\JY.R_M7R3]A^V^5NY\C=MW?AWZ5UGQ<_Y'N7_KWC_E72?"OQ-HNB^&
M+FVU+48;:9KUI`DA.2I1!G\P?RKZ"-1T\-&2C?1'@RIJIB91;MJSSC_BHO\`
MJ*?^1*^HZYS_`(3WPK_T'+7\S_A6II>MZ;K<4DFFWD=RD9VN8ST->9BZLZJ3
M<+6/1PM*%)M*=[E^O/\`XQ-*/!*",95KR,2<=%VM_7;7H%<WX]T=];\&:A:Q
M#,Z()HAR<LAW8`'<@$?C6&'DHU8M]S?$1<J4DNQX1X(CCD\;Z,LH&T72,,G'
M(.1^H%?3=?)VG7KZ;JEI?1J&>VF290>Y5@1_*OI*S\:^'+W3!?IJ]K'$%#.L
MLJJZ$]BI.<]?KCC->AF=.3E&26AP9;4BHRBV:;Z3ITES)<OI]JT\N/,E:%2S
MX&!DXR<#BK$%O!;(4@ACB0G)6-0HSZ\5\]^+/'FI:IXCN;C2=4O[6P!"0I%<
M/&&`&-Q`/4G)_*O6OALVJ2^#H+G5;F>XFN':2-IV+,(^`O)YQP3SZURUL+.E
M34Y/?H=-'%0J5'"*^9UU<YX]_P"1$UC_`*]S_,5T=<YX]_Y$36/^O<_S%<]'
M^)'U1T5OX<O1GS7%YGG)Y._S=PV;,[MW;&.]:G_%1?\`44_\B4>%/^1QT3_L
M(0?^C%KZCKW,7BO822Y;W/%PF%]M%OFM8^2)?,\Y_.W^;N._?G=N[YSWKZ4\
M!?\`(B:/_P!>X_F:^?\`Q7_R..M_]A"?_P!&-7T!X"_Y$31_^O<?S-8YB[T8
MO^MC;+E:M)?UN='7.>/?^1$UC_KW/\Q71USGCW_D1-8_Z]S_`#%>31_B1]4>
MI6_AR]&>+?#G3+?6?$LFG7:!H;BTE1N.G`P1[@X(]Q6!JVFW>@:W<6%P2ES:
MR8W*2,]U8>Q&"/K75_"/_D>XO^O>3^5=E\7O"YOM.CUZU0F>T&RX51RT6>&_
MX"3^1)[5[DJ_)B>1[-?B>+&ASX;G6Z?X'FWC#Q'_`,)/<Z9>N?\`28[!(;GY
M<#S%=\D?4$'CUQ7NG@+_`)$31_\`KW'\S7S17TOX"_Y$31_^O<?S-89C!0HQ
MBMKFV7S<ZLI/>QT=<+\7/^1$E_Z^(_YFNZKGO'.C2:[X/U"RA3?<;!)".Y93
MNP/<X(_&O,P\E&K%ON>G7BY4I)=CP[X=)$_C_2!,Y5?,8@C^\$8J/Q.!7TE7
MRGHNI/HVMV6HQC<;:99-O]X`\C\1D5]'1>-/#DNEKJ/]L6B0$`D/*`ZG&=I7
MKN]L5Z&9TY.<9)'!EU2*A*+9XC\3_P#DHNJ_]L?_`$4E>C_!@D^#KH$D@7[@
M>W[N.O'O$>K'7?$5_J9#!;B4L@;J$Z*#R>0`*]\^'.DOH_@FQBE4K-.#<.I[
M;N1_X[MZUIC/<PL8/?3\C/!^_B936VIU5<YX]_Y$36/^O<_S%='7.>/?^1$U
MC_KW/\Q7DT?XD?5'J5OX<O1GS_X4_P"1QT3_`+"$'_HQ:^HZ^6/#EQ%:>)])
MN9W$<,5[#)(YZ*H<$G\J^A/^$]\*_P#0<M?S/^%>GF4)2G'E5SSLNG&,9<SL
M='163I?B;1=:N6MM-U&&YF5#(4C)R%!`S^9'YUK5Y,HN+LU8]2,E)73.%^+G
M_(B2_P#7Q'_,UY1\.5B;X@:0)CA/,8CG^((Q7]<5[AXYT:37?!^H64*;[C8)
M(1W+*=V![G!'XU\Z:+J3Z-K=EJ,8W&VF63;_`'@#R/Q&17L8'W\/*"WU_%'D
M8WW,1&;VT_!GU97SG\3_`/DHNJ_]L?\`T4E>W1>-/#DNEKJ/]L6B0$`D/*`Z
MG&=I7KN]L5\[^(]6.N^(K_4R&"W$I9`W4)T4'D\@`5GEM.<:DI-=+&F8U(NF
MDGU/8?@P2?!UT"20+]P/;]W'7HM<K\.=)?1_!-C%*I6:<&X=3VW<C_QW;UKJ
MJX<3)2K2:[G=AHN-**?8\]^,DDB>"X50G:]ZBOQGC:Y_F!7FOPQ`;XB:4"`1
M^]//_7)Z]C^(NE2:OX(OXH0S2P@3HJ_Q;#DCWXS^.*^?]`U:30M>LM3C!8V\
MH9E!P67HRY]P2/QKT\%[^%E!;Z_D>;C/<Q,9O;0]H^(GCK5/"5_906$%G(D\
M1=C.C$@@XXPPKC/^%T>(_P#GRTK_`+]2?_%UW^J/X"\5VD.J:G=V<\<285GN
MVB9`><%0P.?8C->%:Y)ITNMW;:3#Y.G^81`F6/RC@'YB3SC//K2P=*E./+*&
MJW;#%U:L)<T9Z/:Q]&^#=:N?$/A2RU6[2))Y]^Y8@0HVNRC`))Z`=ZW:Y'X8
M?\DZTK_MM_Z->NNKRZZ4:LDN[/4HMRIQ;[(R/%?_`")VM_\`8/G_`/1;5\SZ
M5_R&+'_KXC_]"%?3'BO_`)$[6_\`L'S_`/HMJ^9]*_Y#%C_U\1_^A"O4RW^'
M,\S,?XD3ZOHHHKQCUSR[XV?\@?2O^OA__0:\?LOMOG'[#]H\W;SY&=VW\.W2
MO8/C9_R!]*_Z^'_]!KC_`(5ZOI^B^)[FYU*ZCMH6LFC#R="Q=#C\@?RKW<))
MPPG,E??\SP\5%2Q7*W;8YW_BHO\`J*?^1*]Z^'/VG_A`]-^U^;Y_[W=YN=W^
MM?&<\],5-_PGOA7_`*#EK^9_PJWIWBK0M7NQ:Z?J<%Q.06"(3G`ZUQ8FO4JP
MLX6MJ=N&HPI3NIWN;%%%9?B+5WT'0+O5$M&NC;J'\E6V[AD`G.#@`$GIVK@C
M%R:2.Z344VSQ+QA\-M4T.^EFTVVFO-,;+(T2[FB']U@.>/7I7#D%6((((X(/
M:O5;'XSWDNM6XO;&V@TPOB7RPS2*"",YS@X.#T[5Z'=7/A'6K(W%Y/H]U`1D
MR3/&=O'J>5(S[$5[?UJM12C6C?S1XWU:C6;=*5O)GAGA[QYKOAZXB,=Y+<6J
M\-:SN60KGD#/W3[BOH;1]5M];T>UU*T),-P@<`]5/0J?<$$'Z5\Q:VFGQZW>
MKI3L]@)6$#-G)7MUYQ]:][^%]K-:^`=/\XOF4R2*K#[JESC'L?O?\"K/,:<.
M15$K,TR^I/G=-NZ.PHHHKQSU@HHHH`****`"BBB@#S#XH^$M<\1ZE83:59?:
M(XH65SYJ)@DY_B(K@O\`A6'C'_H#_P#DS#_\77T917=2Q]2G!025E_7<XJN!
MIU)N;;U_KL>!V'PA\373+]J%K9(1EC)*'(Y]%SSWZUZWX4\'Z=X2LFBM-TEQ
M+CSKA_O28SCCH`,]!^M=#16=;&5:RM)Z&E'"4J3O%:A1117*=(5YA\4?"6N>
M(]2L)M*LOM$<4+*Y\U$P2<_Q$5Z?16M&K*E/GCN95J4:L.21YS\*_"^L^&_[
M6_M:S^S_`&CR?*_>H^[;OS]TG'WAUKT:BBE6JNK-SENQTJ2I04([(****S-#
MP7_A7/BO_A)/M?\`97[C[9YN[[1%]W?G.-V>E>]445T5\1*M;FZ&%##QHWY>
MIY#\0_AQJ6H^(/[2T&T$ZW0+7$?F(FR0=_F(X8?7D'U%=#\+O#FK>'--OX=5
MM?L[RS*R#S%?(`Q_"37>T54L74E2]D]OQ)CA81J^U6X5D^)TU"7PSJ$6E0>=
M>RPF.)-P7EOE)R2!P"3U[5K45S1?*TSHDKIH\1\&_#?Q!9^+-/O-5T\06EO)
MYS.9HV^91E0`K$_>Q7MU%%;5\1.O+FD94*$:,>6)YA\4/!.J>(-1L;_1[07$
MHB,4X\Q4(`.5/S$`]6_*H_ACX9\2^&=9NQJ6G>397,(#/YT;8=3\O"L3T+=N
M]>IT5?UN?LO8M*Q'U2'M?:INX4445RG28?B_13X@\*W^G(H:9X]T.<?ZQ>5Y
M/3)&,^A->'_\*P\8_P#0'_\`)F'_`.+KZ,HKJH8RI0BXQL<M?"4ZTN:5S(\+
MZ3_8?AC3M-90LD,($@!R/,/+X/IN)K7HHKFE)R;D^ITQBHI)=`KR/XD>%/%/
MB7Q,);'3/-LH(5CB?SXUW'[S'!8'J<=.U>N45K0K2HRYXK4SK456CRR>ARWP
M^\/W'AOPG#9WD8CNY)'FF0,&PQ.`,C@_*%KH-1LH]2TRZL9L>7<1-$V1GAAB
MK-%1.I*4W-[E1@HP4%L?.A^%_C$,0-(!`[BYBY_\>KW[1VO7T:S.I1>5>^2H
MG3<&P^.>02.OO5VBML1BIUTE)+0QH86%!MQ;U"O'_B!X:\8>*?$+26^E.=/M
MAY=L#<Q#(_B?!?C<?QP!FO8**BA6=&7-%*_F76HJM'ED]#C?ASX1?POH;->1
MA=2NCNG&X-L`)VJ"..G/U/M3/B1X1D\3Z+')8PJ^I6S9B&0I=3]Y<G`]^?3W
MKM:*/K$_:^UZA["'LO9=#P?P]X*\<^'M=M=3M](.Z%OG7[5#AT/#*?G[C_&O
M=T8LBL5*$C)4XR/;CBEHJJ^(E7:<DKBH8>-%-1;"BBBN<W"BBB@`K.\06LU]
MX;U6TMDWSSV<L4:Y`W,R$`9/`Y-:-%.+L[B:NK'SYI_PT\70:E:S2:3M1)D9
MC]IB.`""?XJ^@Z**WQ&)G7:<NAA0PT*%U'J%%%%<YT'C_P`1?!'B+7?%DE[I
MNG^?;F%%#^=&O('/#,#7)_\`"L/&/_0'_P#)F'_XNOHRBN^GF%6$5%):?UW.
M&>`I3DY-O7^NQ\Y_\*P\8_\`0'_\F8?_`(NO3_A=X<U;PYIM_#JMK]G>6960
M>8KY`&/X2:[VBHK8ZI5AR22L51P5.E/GBV%%%%<9V'EGC'X3G4;V74=!DBAD
ME.Z2UDX4MW*GMGTZ>_:N`?X=>+8YQ"=%F+'`!5T*\_[0./UKZ2HKNI9A5A'E
MW.*I@*4WS;'BWAKX/WTUPD_B!TM[=2";:)PSO[$C@#Z$GZ=:]GCC2&)(HD5(
MT`5548"@=`!V%.HK"OB)UG>9O1P\**M`*Q?%UA<ZIX3U*RLXO-N)H2L:;@N3
MD=S@5M45E&3C)270TE%2BXOJ>"^'_ASXKL?$FE7=SI6R""\BED;[1$=JJX).
M`V3P*]ZHHK;$8B5=IRZ&5##QH)J/4\%\0?#GQ7?>)-5N[;2M\$]Y++&WVB(;
ME9R0<%LC@U[!X1L+G2_">FV5Y%Y5Q#"%D3<&P<GN,BMJBG6Q4ZL%"26A-'"P
MI2<XMZA6+XNL+G5/">I65G%YMQ-"5C3<%R<CN<"MJBL(R<9*2Z&\HJ47%]3Q
M_P"'7@CQ%H7BR.]U+3_(MQ"ZE_.C;DCCA6)KUV6*.>%X94#QR*5=3T(/!%/H
MK2O7E6GSRW,Z-"-&/+'8\!UCX5>(H-8NH]+L#<V(<F"4SQJ2IY`(+`Y'0\=J
M]D\(V%SI?A/3;*\B\JXAA"R)N#8.3W&16U15UL74K149="*.%A1DY1ZA1117
M,=)Y3XU^%,E_>R:EX?,2/*=TMHYV@L>I0]!GT.!Z'M7!GX=>+1<>0=%FW],A
MT*_]]9Q^M?25%=U/,*L(\NYPU,!2G+FV/(_!_P`))8+J'4/$+Q_NR'6RC.[)
M[;V'''H,Y]>U>N445SUJ\ZTN:;.FC0A1C:`5B^+K"YU3PGJ5E9Q>;<30E8TW
M!<G([G`K:HK.,G&2DNA<HJ47%]3YS_X5AXQ_Z`__`),P_P#Q='_"L/&/_0'_
M`/)F'_XNOHRBN_\`M.MV7X_YG#_9M+N_P_R/*/ACX-U_P]XDN+O5;#[/`]FT
M2MYT;Y8NAQA6)Z`UZO117'6K2K3YY'71HQHQY8A7E/C7X4R7][)J7A\Q(\IW
M2VCG:"QZE#T&?0X'H>U>K444:TZ,N:`5J,*L>69\VGX=>+1<>0=%FW],AT*_
M]]9Q^M=MX/\`A)+!=0ZAXA>/]V0ZV49W9/;>PXX]!G/KVKURBNJIF-:<>5:'
M-3R^E"5WJ%%%%<!W!7D'B_X23RWLE[X<$7EO\S6;-MVM_L$\8]CC'TZ>OT5M
M1KSHRYH&-:A"M&TSYN7X<^+6G,(T67>.YD0+_P!];L?K713_``>U6#PXTZ2)
M<:L9%*VT3@($YR-S8!;D'TX/7->WT5U2S*L[6LCFCEU)7O=G.>`]+O-&\%Z?
MI^H0^3=1>9OCW!L9D9AR"1T(KHZ**X9R<Y.3ZG;"*A%170SO$%K-?>&]5M+9
M-\\]G+%&N0-S,A`&3P.37ANG_#3Q=!J5K-)I.U$F1F/VF(X`()_BKZ#HK>AB
MIT8N,4M3"MA85FI2;T"BBBN8Z3@OBCX<U;Q'IMA#I5K]H>*9F<>8J8!&/XB*
M\P_X5AXQ_P"@/_Y,P_\`Q=?1E%=E''5*4.2*5CCK8*G5GSR;/G/_`(5AXQ_Z
M`_\`Y,P__%UUGPZ\$>(M"\61WNI:?Y%N(74OYT;<D<<*Q->P45=3,*LXN+2U
M_KN3#`4H24DWI_78*9+%'/"\,J!XY%*NIZ$'@BGT5P'<>+>)?@_?0W#S^'W2
MXMV)(MI7"NGL">"/J0?KUKE?^%=^+?/\G^Q9]^<9WIM_[ZSC]:^DZ*]"&95H
MJSLS@GEU*3NKH\6\-?!Z_FN8Y_$$B6]NI!-M&^YY/8L.%'N"3].M>S111P0I
M#$@2.-0J*.@`X`I]%<U?$5*SO,Z:.'A15H!1116!L%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
..4444`%%%%`!1110!_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
